Tissue distribution of perlecan domains III and V during embryonic and fetal human development

Histology and Histopathology

Volumn 24, Issue 7, 2009, Pages 859-868

  Roediger, Matthias ^a   Kruegel, Jenny ^a   Miosge, Nicolai ^a   Gersdorff, Nikolaus ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Basement membrane; Human embryogenesis; Immunohistochemistry; Perlecan

Indexed keywords

MURINAE;

PERLECAN; PROTEOHEPARAN SULFATE;

ARTICLE; BASEMENT MEMBRANE; CHEMISTRY; FETUS DEVELOPMENT; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PRENATAL DEVELOPMENT; PROTEIN TERTIARY STRUCTURE; TISSUE DISTRIBUTION;

BASEMENT MEMBRANE; FETAL DEVELOPMENT; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN STRUCTURE, TERTIARY; TISSUE DISTRIBUTION;

EID: 68849129915     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Arikawa-Hirasawa E., Watanabe H., Takami H., Hassell J.R. and Yamada Y. (1999). Perlecan is essential for cartilage and cephalic development. Nat. Genet. 23, 354-358.
2. Arikawa-Hirasawa E., Wilcox W.R., Le A.H., Silverman N., Govindraj P., Hassell J.R. and Yamada Y. (2001). Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat. Genet. 27, 431-434.
3. Arikawa-Hirasawa E., Le A.H., Nishino I., Nonaka I., Ho N.C., Francomano C.A., Govindraj P., Hassell J.R., Devaney J.M., Spranger J., Stevenson R.E., Iannaccone S., Dalakas M.C. and Yamada Y. (2002). Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet. 70, 1368-1375.
4. Bengtsson E., Morgelin M., Sasaki T., Timpl R., Heinegard D. and Aspberg A. (2002). The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J. Biol. Chem. 277, 15061-15068.
5. Bix G. and Iozzo R.V. (2008). Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis. Microsc. Res. Tech. 71, 339-348.
6. Bretschneider H.J. (1980). Myocardial protection. Thorac. Cardiovasc. Surg. 28, 295-302.
7. Brown J.C., Sasaki T., Gohring W., Yamada Y. and Timpl R. (1997). The C-terminal domain V of perlecan promotes beta1 integrinmediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur. J. Biochem./FEBS 250, 39-46.
8. Burri P.H. (1984). Fetal and postnatal development of the lung. Annu. Rev. Physiol. 46, 617-628.
9. Carlin B., Jaffe R., Bender B. and Chung A.E. (1981). Entactin, a novel basal lamina-associated sulfated glycoprotein. J. Biol. Chem. 256, 5209-5214.
10. Costell M., Carmona R., Gustafsson E., Gonzalez-Iriarte M., Fassler R. and Munoz-Chapuli R. (2002). Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ. Res. 91, 158-164.
11. Costell M., Gustafsson E., Aszodi A., Morgelin M., Bloch W., Hunziker E., Addicks K., Timpl R. and Fassler R. (1999). Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 147, 1109-1122.
12. Couchman J.R., Ljubimov A.V., Sthanam M., Horchar T. and Hassell J.R. (1995). Antibody mapping and tissue localization of globular and cysteine-rich regions of perlecan domain III. J. Histochem. Cytochem. 43, 955-963.
13. French M.M., Smith S.E., Akanbi K., Sanford T., Hecht J., Farach-Carson M.C. and Carson D.D. (1999). Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J. Cell Biol. 145, 1103-1115.
14. Friedrich M.V., Gohring W., Morgelin M., Brancaccio A., David G. and Timpl R. (1999). Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J. Mol. Biol. 294, 259-270.
15. Gersdorff N., Kohfeldt E., Sasaki T., Timpl R. and Miosge N. (2005). Laminin gamma3 chain binds to nidogen and is located in murine basement membranes. J. Biol. Chem. 280, 22146-22153.
16. Girós A., Morante J., Gil-Sanz C., Fairén A. and Costell M. (2007). Perlecan controls neurogenesis in the developing telencephalon. BMC Dev. Biol. 7, 29.
17. Gonzalez E.M., Reed C.C., Bix G., Fu J., Zhang Y., Gopalakrishnan B., Greenspan D.S. and Iozzo R.V. (2005). BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 280, 7080-7087.
18. Grobstein C. (1956). Inductive tissue interaction in development. Adv. Cancer. Res. 4, 187-236.
19. Handler M., Yurchenco P.D. and Iozzo R.V. (1997). Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 210, 130-145.
20. Hassell J., Yamada Y. and Arikawa-Hirasawa E. (2002). Role of perlecan in skeletal development and diseases. Glycoconj. J. 19, 263-267.
21. Hassell J.R., Robey P.G., Barrach H.J., Wilczek J., Rennard S.I. and Martin G.R. (1980). Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl. Acad. Sci. USA 77, 4494-4498.
22. Hopf M., Gohring W., Kohfeldt E., Yamada Y. and Timpl R. (1999). Recombinant domain IV of perlecan binds to nidogens, lamininnidogen complex, fibronectin, fibulin-2 and heparin. Eur. J. Biocem./FEBS 259, 917-925.
23. Hopf M., Gohring W., Mann K. and Timpl R. (2001). Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J. Mol. Biol. 311, 529-541.
24. Knox S.M. and Whitelock J.M. (2006). Perlecan: how does one molecule do so many things? Cell. Mol. Life Sci. 63, 2435-2445.
25. Kohfeldt E., Sasaki T., Gohring W. and Timpl R. (1998). Nidogen-2: a new basement membrane protein with diverse binding properties. J. Mol. Biol. 282, 99-109.
26. Kokenyesi R. and Silbert J.E. (1995). Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 211, 262-267.
27. Kühn K. (1995). Basement membrane (type IV) collagen. Matrix Biol. 14, 439-445.
28. Melrose J., Smith S., Ghosh P. and Whitelock J. (2003). Perlecan, the multidomain heparan sulfate proteoglycan of basement membranes, is also a prominent component of the cartilaginous primordia in the developing human fetal spine. J. Histochem. Cytochem. 51, 1331-1341.
29. Melrose J., Roughley P., Knox S., Smith S., Lord M. and Whitelock J. (2006). The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J. Biol. Chem. 281, 36905-36914.
30. Miosge N., Simniok T., Sprysch P. and Herken R. (2003). The collagen type XVIII endostatin domain is co-localized with perlecan in basement membranes in vivo. J. Histochem. Cytochem. 51, 285-296.
31. Moore K.L. (1982). The developing human. Saunders. Philadelphia.
32. Murdoch A.D., Liu B., Schwarting R., Tuan R.S. and Iozzo R.V. (1994). Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J. Histochem. Cytochem. 42, 239-249.
33. Nicole S., Davoine C.S., Topaloglu H., Cattolico L., Barral D., Beighton P., Hamida C.B., Hammouda H., Cruaud C., White P.S., Samson D., Urtizberea J.A., Lehmann-Horn F., Weissenbach J., Hentati F. and Fontaine B. (2000). Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat. Genet. 26, 480-483.
34. Noonan D.M. and Hassell J.R. (1993). Perlecan, the large low-density proteoglycan of basement membranes: structure and variant forms. Kidney Int. 43, 53-60.
35. Noonan D.M., Fulle A., Valente P., Cai S., Horigan E., Sasaki M., Yamada Y. and Hassell J.R. (1991). The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J. Biol. Chem. 266, 22939-22947.
36. Olsen B.R. (1999). Life without perlecan has its problems. J. Cell Biol. 147, 909-912.
37. O'Rahilly R. and Muller F. (1987). Developmental stages in human embryos. Including a revision of streeter's "horizon" and a survey of the Carnegie collection. Carnegie Institution of Washington Publication 637. Washington.
38. O'Rahilly R. and Muller F. (1996). Human embryology and teratology. 2nd ed. Wiley-Liss. New York. pp 149-157.
39. Roskams T., De Vos R., David G., Van Damme B. and Desmet V. (1998). Heparan sulphate proteoglycan expression in human primary liver tumours. J. Pathol. 185, 290-297.
40. Sadler T.W. (2005). Embryology of neural tube development. Am. J. Genet. C. Semin. Med. Genet. 135C, 2-8.
41. Saxen L. and Sariola H. (1987). Early organogenesis of the kidney. Pediatr. Nephrol. (Berlin, Germany) 1, 385-392.
42. Schulze B., Sasaki T., Costell M., Mann K. and Timpl R. (1996). Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III. Matrix Biol. 15, 349-357.
43. Segev A., Nili N. and Strauss B.H. (2004). The role of perlecan in arterial injury and angiogenesis. Cardiovasc. Res. 4, 603-610.
44. Smith L.T. and Holbrook K.A. (1986). Embryogenesis of the dermis in human skin. Pediatr. Dermatol. 3, 271-280.
45. Soulintzi N. and Zagris N. (2007). Spatial and temporal expression of perlecan in the early chick embryo. Cells Tissues Organs 4, 243-256.
46. Tapanadechopone P., Hassell J.R., Rigatti B. and Couchman J.R. (1999). Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem. Biophys. Res. Commun. 265, 680-690.
47. Tesche F. and Miosge N. (2004). Perlecan in late stages of osteoarthritis of the human knee joint. Osteoarthritis Cartilage 12, 852-862.
48. Timpl R. and Aumailley M. (1989). Biochemistry of basement membranes. Adv. Nephrol. Necker Hosp. 18, 59-76.
49. Timpl R., Rohde H., Robey P.G., Rennard S.I., Foidart J.M. and Martin G.R. (1979). Laminin--a glycoprotein from basement membranes. J. Biol. Chem. 254, 9933-9937.
50. Wenink A.C. (1976). Development of the human cardiac conducting system. J. Anat. 121, 617-631.
51. Zoeller J.J., McQuillan A., Whitelock J., Ho S.Y. and Iozzo R.V. (2008). A central function for perlecan in skeletal muscle and cardiovascular development. J. Cell Biol. 181, 381-394.